Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | ACE | P12821 | 5/20 | 0.39 |
| ▸ | CTSK | P43235 | 2/20 | 0.38 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.38 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.38 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24252141 | 0.88 | SLC1A3 (0.44) | CTSBACESLC1A3SLC1A2SLC1A1 | |
| SCHEMBL27530431 | 0.84 | CTSB (0.44) | CTSBCTSKSLC1A3SLC1A2SLC1A1 | |
| SCHEMBL14282188 | 0.84 | CTSK (0.42) | CTSBCTSKMEN1CYP1A2CYP2C9 | |
| SCHEMBL24252159 | 0.84 | SMN1; SMN2 (0.39) | MEN1CYP1A2CYP2C9CYP2C19KMT2A | |
| SCHEMBL27389520 | 0.78 | SLC1A3 (0.41) | CTSBSLC1A3SLC1A2SLC1A1MEN1 | |
| SCHEMBL10873777 | 0.77 | SLC1A1 (0.45) | SLC1A3SLC1A2SLC1A1MEN1CYP1A2 | |
| SCHEMBL7084082 | 0.76 | PPARA (0.39) | CTSBCTSK | |
| SCHEMBL5268183 | 0.76 | ALDH1A1 (0.40) | CTSBSLC1A3SLC1A2SLC1A1MEN1 | |
| SCHEMBL27744904 | 0.76 | ALDH1A1 (0.40) | CTSBSLC1A3SLC1A2SLC1A1MEN1 | |
| SCHEMBL16166282 | 0.75 | SLC1A3 (0.41) | SLC1A3SLC1A2SLC1A1MEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1140058-B1 | N-FORMYL HYDROXYLAMINE DERIVATIVES AS ANTIBACTERIAL AGENTS | BRITISH BIOTECH PHARM (GB) | 2003-11-05 | — | — | EP | disclosed |
| US-20030149084-A1 | Cytostatic agents | AYSCOUGH ANDREW PAUL (GB) | 2003-08-07 | — | — | US | disclosed |
| US-6495597-B1 | N-FORMYL HYDROXYLAMINE DERIVATIVES | BRITISH BIOTECH PHARMACEUTICALS LTD. (GB) | 2002-12-17 | — | — | US | disclosed |
| US-6476067-B1 | N-formyl hydroxylamine derivatives as antibacterial agents | BRITISH BIOTECH (GB) | 2002-11-05 | — | — | US | disclosed |
| EP-1146868-A1 | ANTI-INFLAMMATORY AGENTS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2001-10-24 | — | — | EP | disclosed |
| EP-1140058-A1 | N-FORMYL HYDROXYLAMINE DERIVATIVES AS ANTIBACTERIAL AGENTS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2001-10-10 | — | — | EP | disclosed |
| EP-1054861-A1 | CYTOSTATIC AGENTS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2000-11-29 | — | — | EP | disclosed |
| WO-2000043001-A1 | ANTI-INFLAMMATORY AGENTS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2000-07-27 | — | — | WO | disclosed |
| WO-2000035440-A1 | N-FORMYL HYDROXYLAMINE DERIVATIVES AS ANTIBACTERIAL AGENTS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2000-06-22 | — | — | WO | disclosed |
| WO-1999041232-A1 | CYTOSTATIC AGENTS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1999-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149084-A1 | Cytostatic agents | MCTS1, NNMT, MMP12 | CTSB 659/4885ACE 2167/4885CTSK 1006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.